Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial re ...